Acadia Pharmaceuticals

With the FDA approval of Nuplazid, Acadia Pharmaceuticals launched the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. With a robust pipeline of products targeting CNS disorders, Acadia is becoming a company to watch in this therapeutic area, and this new exhibit promoting Nuplazid makes a strong statement to the CNS market.

face to face marketing strategies